PubRank

Tatsu Shimoyama

Author PubWeight™ 16.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006 1.81
2 Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 2005 1.75
3 Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007 1.55
4 Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005 1.50
5 Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006 1.25
6 Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2007 1.18
7 Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. FASEB J 2005 0.87
8 Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 2005 0.82
9 Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010 0.81
10 Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol 2010 0.81
11 Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother Pharmacol 2005 0.81
12 Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer. Jpn J Clin Oncol 2002 0.78
13 [A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime)]. Gan To Kagaku Ryoho 2009 0.78
14 Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2003 0.77
15 [A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy]. Gan To Kagaku Ryoho 2011 0.76
16 Translational studies for target-based drugs. Cancer Chemother Pharmacol 2005 0.76
17 [Efficacy of Amrubicin Monotherapy for Patients with Extrapulmonary Neuroendocrine Carcinomas Refractory to Platinum-Based Chemotherapy]. Gan To Kagaku Ryoho 2020 0.75